2017 ACVIM Forum Research Abstract Program

Based on the encouraging safety data in our healthy canine patients, this adoptive T cell transfer approach has the potential to change treatment recommendations and outcome in dogs diagnosed with osteosarcoma. A phase I/II clinical trial is ongoing to determine if ECI-OSA-1 after amputation is indeed safe and results in similar or enhanced efficacy compared to surgery and chemotherapy. Exosomes are small lipid vesicles that mediate cell-to-cell communication. Cancer cells exploit exosomes to promote metastasis, evade host immune responses, and facilitate angiogenesis. Presently, the effects of osteosarcoma (OSA) exosomes on healthy osteoblasts have not been studied. This is the first study to investigate the proteomic composition of canine OSA exosomes and their impact on osteoblasts. We hypothesized that OSA exosomes carry a unique cargo which manipulates healthy osteoblasts, resulting in alteration of bone turnover.